Ocular Therapeutix, Inc. (OCUL)
Last Price$8.511.2%
Market Cap$1,347.5M
OCUL Rating
OCUL Quality rating performance
OCUL Intrinsic Value
Key Highlights:
As of Mar 11, 2025 OCUL Relative Value is $8.9, which is undervalued by 4.8%, compared to current share price of $8.5.
As of Mar 11, 2025 OCUL DCF Value is N/A, which is undervalued by N/A, compared to current share price of $8.5.
OCUL Share Price History
1W 30.9%
1M 14.4%
6M 0.8%
YTD 76.9%
1Y (12.5%)
3Y 60.3%
5Y 59.1%
10Y (80.2%)
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
OCUL Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$1,347.5M
$1,031.2M
$63.7M
($136.0M)
Shares Outstanding
158M
Employees
274
Growth (CAGR)
72.0%
14.9%
(8.08%)
11.2%
11.7%
(0.49%)
Profitability
91.2%
(269.8%)
(304.0%)
(211.5%)
(213.6%)
70.3%
Intrinsic Value
$9.6 (12.3% undervalued)
N/A
$9.6
($2.0)
($7.0)
(100.0%)
(158.3%)
Valuation (LTM)
Return on Capital
Financial Health
($316.3M)
2.3x
(12.7x)
24.0%
Dividends
Earnings
Aug 04, 2025
MISS by (0.2%)
MISS by 17.2%
2 Beat & 8 Miss
OCUL Stock Financials
OCUL Income Statement Metrics
Annual
Quarterly
LTM
OCUL Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
($134.7M) +107.0% YoY
Capital Expenditure (CAPEX)
($1,288.0K) -78.8% YoY
Free Cash Flow (FCF)
($136.0M) +91.1% YoY
OCUL Income Statement Overview
Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
OCUL Balance Sheet Overview
Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
Assets
Liabilities
Total assets
$457.9M
Current assets ($441.0M, 96.3% of total)
$392.1M (85.6%)
$32.4M (7.1%)
Other current assets
$16.5M (3.6%)
Non-current assets ($16.9M, 3.7% of total)
$0.0 (0.0%)
$15.3M (3.3%)
$0.0 (0.0%)
Other non-current assets
$1,614.0K (0.4%)
Financial position
($316.3M)
Cash & Short-term
Investments
Total Debt
OCUL Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
OCUL Earnings Surprises
Crunching data... Almost there!
OCUL Dividends
OCUL Dividend Yield
Crunching data... Almost there!
OCUL Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with OCUL
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$1,347.5M | 6.1 | $9.6 12.3% undervalued | (12.5%) | $63.7M | ($136.0M) | 9.2% | (213.6%) | 91.2% | (375.6%) | 24.0% | |
$124.8B | 5.7 | $187.5 61.6% overvalued | 17.8% | $11.0B | ($790.3M) | 11.5% | (7.2%) | 86.1% | (15.0%) | 10.7% | |
$77.0B | 6.3 | $1,048.3 46.0% undervalued | (25.4%) | $14.2B | $3,597.2M | 8.3% | 25.3% | 84.5% | 25.7% | 5.7% | |
$34.4B | 5.8 | $123.0 78.8% overvalued | 50.8% | $2,258.9M | ($211.2M) | 127.3% | (9.4%) | 86.8% | (41.3%) | N/A | |
$30.7B | 5.2 | $91.8 61.6% overvalued | 60.1% | $2,248.2M | ($42.6M) | 23.0% | (1.9%) | 85.6% | (7.2%) | 1,931.9% | |
$24.0B | 5.9 | $191.1 94.2% undervalued | 2.2% | €2,751.1M | (€229.8M) | (28.0%) | (8.4%) | 80.3% | (37.8%) | 1.3% | |
$14.5B | 5.4 | $71.6 120.5% undervalued | 11.2% | $2,263.9M | $2,769.0M | (3.8%) | 122.3% | 73.9% | 14.5% | 73.6% | |
$13.8B | 7.7 | $542.2 78.1% undervalued | 22.0% | $2,877.4M | $1,080.6M | 23.6% | 37.6% | 89.2% | 65.4% | 4.7% | |
$13.4B | 6.7 | $46.9 33.5% overvalued | (18.0%) | $2,850.5M | $475.4M | 17.8% | 16.7% | 78.6% | 11.0% | 10.7% | |
$13.3B | 5.9 | $0.6 96.9% overvalued | 330.2% | $0.0 | ($142.1M) | N/A | N/A | N/A | (3,335.4%) | 1.9% | |
$1,846.9M | 5.5 | $2,745.6 1,111.0% undervalued | 39.9% | $3,316.8M | ($1,041.0M) | 50.5% | (31.4%) | 83.7% | (43.2%) | 32.1% |
FAQ
What is Ocular Therapeutix, Inc. (OCUL) stock rating?
As of today, Ocular Therapeutix, Inc. has a stock rating of 6 (out of 10), which is considered Good.
is Ocular Therapeutix, Inc. (OCUL) a good stock to buy?
As of today, Ocular Therapeutix, Inc. has a Good stock rating, which is 12.3% undervalued. According to Value Sense backtesting, stocks with similar profile tend to outperform the market by 3.2%.